Carcinoma: Page 2

Bayer, Tempus join forces on cancer testing
By LabPulse.com staff writers
The assay will be available for a subset of patients with metastatic colorectal cancer (mCRC), as well as those with radioactive iodine refractory differentiated metastatic thyroid carcinoma (RAIR thyroid cancers).
December 10, 2020
2019 05 22 19 44 5254 Dna Red Laser 400
Prelude highlights ASTRO data on breast cancer risk test
By LabPulse.com staff writers
The study included nearly 1,800 women diagnosed with ductal carcinoma in situ (DCIS) and classified as low risk by radiation oncology/toxicity grading-like criteria for recurrence of DCIS or progression to invasive breast cancer. The DCISionRT assay reclassified almost half of these patients to elevated risk, which suggests numerous patients would have been undertreated with surgery alone.
October 29, 2020
2016 10 05 17 45 45 493 Breast Cancer 400
Fujifilm Medical to add IVD to portfolio
By LabPulse.com staff writers
Fujifilm Wako Diagnostics has developed biomarkers that assess the risk of hepatocellular carcinoma in patients with chronic liver disease, as well as IVD reagents for disorders of lipid metabolism, lupus, rheumatoid arthritis, coronary heart disease, and diabetes, according to Fujifilm Medical Systems.
August 16, 2020
2020 08 17 23 11 0044 Fujifilm Rsna 2019 400
Liver cancer diagnostic test offers promise of early detection
By LabPulse.com staff writers
The platform is called EV Click Chips, and the hope is that it will enable more effective purification of extracellular vesicles in blood from people with hepatocellular carcinoma. Researchers from the University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center have received a $2.97 million grant from the U.S. National Cancer Institute (NCI) to develop the technology further.
August 4, 2020
2020 01 22 00 12 9591 Liver Cancer 400
Supplementing imaging with urine test boosts detection of adrenal cancer
By Leah Sherwood
The researchers proposed a "triple test strategy" that combines a urine test, computed tomography (CT), and characterization of the tumor size (specifically, whether the maximum tumor diameter was less than 4 cm or greater than or equal to 4 cm). This trifecta of criteria had the highest specificity and sensitivity of any of the tested methods.
July 27, 2020
2020 07 27 17 12 4438 Adrenal Gland 400
Molecular genotyping shines light on serous ovarian cancer
By Emily Hayes
High-grade serous ovarian cancer is the most malignant form of ovarian cancer, causing up to 70% of ovarian cancer deaths. The new study validated a new classifier tool called the predictor of high-grade serous ovarian carcinoma (HGSOC) molecular subtype (ProType), which encompasses 55 genes plus five housekeeping genes and is based on the NanoString platform.
June 17, 2020
2020 06 17 23 55 4085 Double Helix Strange Cancer Cell 400
Google reports pathology AI helps predict survival in cancer patients
By Emily Hayes
The deep-learning system was developed and tested using histopathology slides for patients with 10 cancer types -- including bladder cancer, invasive breast cancer, and head and neck squamous cell carcinoma -- drawing from publicly available data from the Cancer Genome Atlas (TCGA) program.
June 17, 2020
2020 06 16 21 12 7935 Artificial Intelligence Ai Hand 400
Blood test identifies patients at risk for liver cancer
By LabPulse.com staff writers
The test analyzes patients' previous viral exposure to accurately predict whether they might develop hepatocellular carcinoma (HCC). It was created by researchers from the U.S. National Institutes of Health and several academic centers to help improve liver cancer screening and early detection.
June 11, 2020
2019 08 20 22 16 4501 Liver Anatomy 400
Study calls for hepatitis D screening in at-risk patients
By LabPulse.com staff writers
A review of the literature suggests that those who have hepatitis D along with hepatitis B have up to three times the risk for developing hepatocellular carcinoma than if they had hepatitis B alone, reported researchers at the University of Geneva and Geneva University Hospitals, in an article in press. This assessment was based on an analysis of data from 93 studies including a total of more than 100,000 patients.
May 19, 2020
2020 05 19 23 52 8693 2020 05 20 Hepatitis D 400
FDA approves Agilent assay for lung cancer
By LabPulse.com staff writers
The test, called PD-L1 IHC 28-8 pharmDx, will help physicians identify patients with metastatic NSCLC who qualify for treatment with a dual immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy), both of which are manufactured by Bristol Myers Squibb.
May 17, 2020
2020 03 04 21 09 7509 2020 03 05 Penn Tmb Lung 20200304211703
Bayer, NeoGenomics offer free genomic testing for thyroid, colorectal cancers
By LabPulse.com staff writers
Under the program, genomic cancer testing for NTRK gene fusions will be available at no cost for patients with RAI-refractory (RAI-R) differentiated thyroid carcinoma and metastatic colorectal cancer (mCRC) with high microsatellite instability (MSI-H). More commonly found in these patients, NTRK fusions have been shown to drive tumor growth and may play a role in disease management, according to the companies.
May 5, 2020
2019 04 22 23 41 4967 Cancer Cell Target2 400
Study urges broader genetic testing of breast cancer patients
By Kate Madden Yee
The National Comprehensive Cancer Network's (NCCN) current guidelines for genetic testing recommend it for women younger than 46 who are diagnosed with breast cancer, regardless of family history or cancer subtype. But expanding the age range for genetic testing would help identify more women with mutations that make them vulnerable, concluded first author Dr. Siddhartha Yadav, a hematology-oncology fellow at the Mayo Clinic in Rochester, MN, and colleagues.
March 3, 2020
2019 12 13 21 10 9322 Dna Sequencing 400
Previous Page
Page 2 of 3
Next Page